News und Analysen
EQS-News: Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
EQS-News: Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
EQS-News: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
EQS-News: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
EQS-Adhoc: Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
EQS-Adhoc: Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
EQS-News: Evotec receives € 150 m loan from European Investment Bank
EQS-News: Evotec receives € 150 m loan from European Investment Bank
EQS-News: Carl Zeiss Meditec achieves further revenue growth in Q1 2022/23 – Orders on hand remain high
EQS-News: Carl Zeiss Meditec achieves further revenue growth in Q1 2022/23 – Orders on hand remain high
EQS-News: Evotec and Related Sciences expand integrated drug discovery and development partnership
EQS-News: Evotec and Related Sciences expand integrated drug discovery and development partnership
EQS-News: Evotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer
EQS-News: Evotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer
EQS-News: Evotec announces agreement with Janssen to develop immune-based therapies
EQS-News: Evotec announces agreement with Janssen to develop immune-based therapies
EQS-News: MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
EQS-News: MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
EQS-News: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
EQS-News: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
EQS-News: Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
EQS-News: Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
Evotec achieves further progress in neuroscience collaboration with Bristol Myers Squibb
Evotec achieves further progress in neuroscience collaboration with Bristol Myers Squibb
EQS-News: MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022
EQS-News: MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022
EQS-News: MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022
EQS-News: MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022
EQS-News: Carl Zeiss Meditec remains on growth course in fiscal year 2021/22
EQS-News: Carl Zeiss Meditec remains on growth course in fiscal year 2021/22
EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program
EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program
EQS-News: MorphoSys AG: Financial Calendar 2023
EQS-News: MorphoSys AG: Financial Calendar 2023
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
EQS-News: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
EQS-News: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
EQS-Adhoc: Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
EQS-Adhoc: Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
EQS-News: Evotec SE reports results for the first nine months 2022 and provides corporate update
EQS-News: Evotec SE reports results for the first nine months 2022 and provides corporate update
EQS-News: MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
EQS-News: MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
EQS-News: Evotec SE to announce results for the first nine months 2022 on 09 November 2022
EQS-News: Evotec SE to announce results for the first nine months 2022 on 09 November 2022